The latest price target for Tarsus Pharmaceuticals (NASDAQ:TARS) was reported by Goldman Sachs on November 15, 2024. The analyst firm set a price target for $41.00 expecting TARS to fall to within 12 months (a possible -8.13% downside). 12 analyst firms have reported ratings in the last year.

The latest analyst rating for Tarsus Pharmaceuticals (NASDAQ:TARS) was provided by Goldman Sachs, and Tarsus Pharmaceuticals maintained their neutral rating.

There is no last upgrade for Tarsus Pharmaceuticals

There is no last downgrade for Tarsus Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tarsus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tarsus Pharmaceuticals was filed on November 15, 2024 so you should expect the next rating to be made available sometime around November 15, 2025.

While ratings are subjective and will change, the latest Tarsus Pharmaceuticals (TARS) rating was a maintained with a price target of $36.00 to $41.00. The current price Tarsus Pharmaceuticals (TARS) is trading at is $44.63, which is out of the analyst’s predicted range.